Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.
Authors: Chan SL; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Electronic address: chanlam_stephen@cuhk.edu.hk., Finn RS; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Edeline J; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Ogasawara S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan., Knox JJ; Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada., Daniele B; Department of Oncology, Ospedale del Mare, Naples, Italy., Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Merle P; Department of Hepatology and Gastroenterology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France., Bouattour M; Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Liver Cancer and Innovative Therapy Unit Hôpital Beaujon, Clichy, France., Lim HY; Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea., Chao Y; Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan., Yau T; Department of Medicine, The University at Hong Kong, Pok Fu Lam, Hong Kong, China., Haber BA; Clinical Research (Barbara Anne Haber, Usha Malhotra, Abby B. Siegel) and Biostatistics (Chih-Chin Liu), Merck & Co., Inc., Rahway, NJ, USA., Malhotra U; Clinical Research (Barbara Anne Haber, Usha Malhotra, Abby B. Siegel) and Biostatistics (Chih-Chin Liu), Merck & Co., Inc., Rahway, NJ, USA., Siegel AB; Clinical Research (Barbara Anne Haber, Usha Malhotra, Abby B. Siegel) and Biostatistics (Chih-Chin Liu), Merck & Co., Inc., Rahway, NJ, USA., Liu CC; Clinical Research (Barbara Anne Haber, Usha Malhotra, Abby B. Siegel) and Biostatistics (Chih-Chin Liu), Merck & Co., Inc., Rahway, NJ, USA., Kudo M; Department of Gastroenterology and Hepatology, School of Medicine, Kindai University, Osaka, Japan., Cheng AL; National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.
Source: Annals of hepatology [Ann Hepatol] 2026 Jan-Jun; Vol. 31 (1), pp. 102169. Date of Electronic Publication: 2025 Dec 24.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Fundación Clínica Médica Sur Country of Publication: Mexico NLM ID: 101155885 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1665-2681 (Print) Linking ISSN: 16652681 NLM ISO Abbreviation: Ann Hepatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1665-2681
DOI:10.1016/j.aohep.2025.102169